Skip to content

Left atrial appendage occlusion via the guidance of intracardiac echocardiography in patients with nonvalvular atrial fibrillation and left atrial appendage thrombus

Left atrial appendage occlusion via the guidance of intracardiac echocardiography in patients with nonvalvular atrial fibrillation and left atrial appendage thrombus

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097054
Enrollment
Unknown
Registered
2025-02-11
Start date
2024-10-02
Completion date
Unknown
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Interventions

Intracardiac echocardiography guided left atrial appendage occlusion group:Treat left atrial appendage thrombus by left atrial appendage occlusion via the guidance of intracardiac echocardiography

Sponsors

The First Affiliated Hospital of Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Patients with non-valvular atrial fibrillation aged >=18 years; 2) the presence of left atrial appendage thrombus confirmed by esophageal ultrasound; 3) one of the following conditions: (1) left atrial appendage thrombosis is still present after continuous treatment with at least one anticoagulant drug at a standard dose for not less than 6 weeks; (2) there are contraindications to anticoagulant drug treatment; (3) the patient refuses to accept anticoagulant drug treatment and requires left atrial appendage occlusion; 4) Subjects or their legal representatives voluntarily participate in the trial and sign a written informed consent form.

Exclusion criteria

Exclusion criteria: (1) valvular atrial fibrillation; (2) left atrial appendage thrombus prominent to the left atrium, or preprocedural imagine indicates that it is not suitable to perform left atrial appendage occlusion; (3) coexistence with left atrial thrombus; (4) myocardial infarction, ischemic stroke, or transient ischemic attack within 30 days; (5) sever heart failure, renal disfunction, or liver disfunction; (6) life expectancy less than 1 year.

Design outcomes

Primary

MeasureTime frame
Periprocedural major adverse events;

Secondary

MeasureTime frame
Periprocedural minor adverse events;

Countries

China

Contacts

Public ContactHuimin Chu

The First Affiliated Hospital of Ningbo University

epnbheart@163.com+86 135 6633 6742

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026